|
|
|
|
|
|
As therapeutic modalities become increasingly complex, development and manufacturing success depend on access to specialized expertise, advanced technologies, and purpose-built facilities. Whether producing mammalian cell culture–derived biologics or highly potent active pharmaceutical ingredients (HPAPIs), sponsors face unique challenges related to process development, scale-up, quality, containment, regulatory compliance, and commercialization.
This edition of the Outsourced Pharma Capabilities Update (OPCU) highlights the capabilities CDMOs bring to complex biologics and potent compound manufacturing, showcasing expertise across cell line development, upstream and downstream processing, GMP production, containment technologies, occupational safety, and process scale-up. Join us to explore the facilities, technical platforms, and manufacturing strategies that help sponsors mitigate risk, accelerate development timelines, and successfully advance innovative therapies from early development through commercial production.
Recent Sessions Available On-Demand
Fill/Finish & Small Molecule – 4/21/2026 & 4/22/2026
Upcoming OPCU Topics & Times
Cell Therapy | 6/16/2026, AM Session
Cell Line Development | 6/16/2026, PM Session
Microbial Development & Manufacturing | 6/17/2026, AM Session
ADCs | 6/17/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.
|
|
|
|
|
|
KBI Biopharma
|
Uncover how advanced cell line development platforms, targeted integration technologies, and data-driven selection tools can accelerate biologics development from DNA to patient with greater speed, stability, and confidence.
|
|
Request Information
|
|
KBI Biopharma
|
|
|
|
AGC Biologics
|
Learn how the Multi-Pack system accelerates scale-up, boosts efficiency, and reduces costs. We'll share real-world case studies on streamlining development and commercialization while meeting evolving clinical and market demands.
|
|
Request Information
|
|
AGC Biologics
|
|
|
|
IDT Biologika
|
Discover how advanced mammalian cell culture platforms, proven process strategies, and end-to-end CDMO capabilities can accelerate biopharmaceutical development. Learn how scalable manufacturing solutions support high-quality biologics production.
|
|
Request Information
|
|
IDT Biologika
|
|
|
|
Novartis Contract Manufacturing
|
Explore a global contract manufacturing network with proven regulatory success, flexible partnership models, and end-to-end capabilities spanning biologics, advanced therapies, and fill-finish to support your program.
|
|
Request Information
|
|
Novartis Contract Manufacturing
|
|
|
|
FUJIFILM Biotechnologies
|
Advance your next biologic, vaccine, or advanced therapy with a global CDMO partner offering end-to-end development and manufacturing services. From cell line development to commercial production, we help bring innovative therapies to market.
|
|
Request Information
|
|
FUJIFILM Biotechnologies
|
|
|
|
|
|
Curia
|
What is critical when choosing a CDMO partner for HPAPI development and manufacturing? Curia's Brian Haney breaks down the key questions, containment strategies, controls, and expertise every innovator should evaluate for long-term success.
|
|
Request Information
|
|
Curia
|
|
|
|
Recipharm
|
Overcome common high-potency development challenges, reduce API consumption, streamline tech transfer, and accelerate timelines. Discover practical strategies for building scalable, reliable manufacturing processes from day one.
|
|
Request Information
|
|
Recipharm
|
|
|
|
Ardena
|
Here, we explain how integrated, science-led CDMO/CRO strategies can manage the full complexity of high-potent drug development — from containment-focused manufacturing and ultra-sensitive analytics to product delivery.
|
|
Request Information
|
|
Ardena
|
|
|
|
Bend Bioscience
|
Take a closer look at how expanded capacity, commercial spray drying capabilities, and targeted investments support seamless progression from development to commercial manufacturing while advancing complex drug programs with confidence.
|
|
Request Information
|
|
Bend Bioscience
|
|
|
|
|
